- Details
- Clara Hwang shares an overview of her ASCO 2022 poster session presentation with Alicia Morgans. Dr. Hwang explains how the research was motivated by the known disparities in Black versus white men regarding prostate cancer diagnosis and prognosis. She then describes how this study explored these disparities within the prostate cancer precision medicine space. Biographies: Clara Hwang, MD, Medical...
|
- Details
- Phil Kantoff, CEO of Convergent Therapeutics, sits down with Alicia Morgans to discuss the future of radioligand therapy in the treatment of advanced prostate cancer. Philip Kantoff provides an overview of exciting results seen in studies on actinium-225, a powerful alpha-emitter tested in patients with advanced prostate cancer that also may be promising for patients with earlier-stage disease. Bi...
|
- Details
- Alicia Morgans and Matthew Smith join Charles Ryan to discuss cancer survivorship. Drs Morgans and Smith explain the holistic role that a cancer survivorship program plays in the health and well-being of prostate cancer patients, including bone health, mental health, monitoring cardiovascular risk, and more. Biographies: Matthew R. Smith, MD, Ph.D., Professor of Medicine, Harvard Medical School, A...
|
- Details
- Veda Giri joins Charles Ryan in a discussion on the EXPAND Network, EX tending P rostate Cancer Genetic A wareness, N avigation, and D elivery for genetic testing, and genetic awareness in males of African descent for Black men. This project is supported by the 2021 PCF-Pfizer Health Equity Challenge Award grant mechanism. Dr. Giri provides the rationale for this project stemming from statistics f...
|
- Details
- Emmanuel Antonarakis joins Alicia Morgans to discuss the immune checkpoint B7-H3 and its implications for prostate cancer treatment. Dr. Antonarakis provides an overview of clinical trials that tested B7-H3 and the encouraging findings of those trials. He also details some of the toxicities noted during the trials and plans for future studies given the measurable disease responses and PSA response...
|
- Details
- Channing Paller joins Alicia Morgans at ASCO 2022 to discuss considerations in the timing and intensity of ADT in biochemical recurrence. Dr. Paller gives an overview of her presentation and the two explore important considerations when timing treatment for prostate cancer after recurrence and relevant clinical trial data, such as TOAD and CRUK. In addition, they acknowledge the importance of pati...
|
- Details
- Alicia Morgans interviews Nicholas James about the RADICALS trial, a complex study aiming to determine the optimal timing for radiotherapy after surgery and the amount of hormone therapy needed. The first question's data showed that waiting was safe and adjuvant therapy unnecessary. The second question, presented at ESMO, involved pragmatic randomization between zero, six, and 24 months of ADT, re...
|
- Details
- Gerhardt Attard joins Ashley Ross in discussing an ancillary study of the STAMPEDE trial assessing the clinical qualification of transcriptome signatures for advanced prostate cancer starting ADT with or without abiraterone acetate and prednisolone. The addition of abiraterone acetate and prednisolone to ADT is the standard of care for advanced prostate cancer (metastatic, M1 and high-risk non-met...
|
- Details
- Alicia Morgans converses with Matthew Smith and Kim Chi about the application of triplet therapy in metastatic hormone sensitive prostate cancer (mHSPC). Dr. Smith outlines the ARASENS study that tests the impact of adding darolutamide, an AR pathway inhibitor, to the standard treatment of androgen deprivation therapy (ADT) and docetaxel. The data suggest a significant survival advantage with trip...
|
- Details
- At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC), Mary Ellen Taplin presents the role of systemic therapy in the treatment of patients with oligometastatic and oligoprogressive prostate cancer. Biographies: Mary Ellen Taplin, MD, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA Related Content: APCCC 2022: What Is the Evidence of Systemic Therapies (Alone or in Com...
|
